The aim of this study is to assess the role of LAT, referred to stereotactic ablative radiotherapy, and to report clinical outcomes of the largest retrospective series, to date, of patients with oligometastatic EGFR/ALK/ROS1 wild type NSCLC. This evidence concerns the gene ALK and non-small cell lung carcinoma.